tbuckley/cabot-search huggingface dataset:
Venous thromboembolism in ovarian cancer patients receiving erythropoietin (Epo)/darbepoetin (Darbe) for chemotherapy-induced anemia (CIA)
Authors: G. Riebandt, S. South, J. DelMonte, S. Lele, K. Odunsi, K. Rodabaugh
Journal: Journal of Clinical Oncology (2008)

16514 Background: Cancer patients are at higher risk of developing venous thromboembolism (VTE) than the general population. With VTE incidence of 5.2% - 5.6%, ovarian cancer ranks third among malignancies associated with the highest incidence of VTE, following kidney (5.7%) and pancreas (8.2%) cancers. Both Epo/Darbe are associated with increased risks of VTE ranging from 4.2% to 7.1%. We reviewed the incidence of VTE among patients with ovarian cancer receiving Epo/Darbe for CIA. Methods: We performed retrospective charts reviews of patients with ovarian malignancy who received Epo/Darbe for CIA in 2005–2006 and who developed VTE during this period. Results: In 2005–2006 among 411 patients with ovarian cancer seen in RPCI Gynecologic Oncology Clinic, 48 (12%) were diagnosed with VTE. During this time 115 ovarian cancer patients were receiving Epo/Darbe for CIA. 13 (11%) of these patients developed VTE while receiving EPO/Darbe, 10 deep venous thrombosis (DVT) and 3 pulmonary embolism (PE). Among them, 9 were treated for recurrent disease and only 1 had a surgery 4 weeks preceding VTE. All 13 patients were receiving chemotherapy during VTE diagnosis: 5 carboplatin/paclitaxel, 6 cisplatin with gemcitabine, 1 docetaxel, and 1 doxorubicin. 10 patients were receiving Darbe for CIA and 3 were receiving Epo. The mean cumulative dose of Darbe was 1410 mcg with mean onset of VTE in130 days from the start of Epo/Darbe. Conclusions: The rate of VTE among RPCI ovarian cancer patients, including those receiving Epo/Darbe appears to be higher than that reported in the literature. This warrants further evaluation of the incidence of VTE among patients with ovarian cancer, especially the subset receiving Epo/Darbe for CIA. Risk Factor Number of Patients (N 13) Time from surgery (weeks) Mean: 48 Age at VTE (years) Mean: 66 <40: 0 40–60: 3 (23%) >60: 10 (77%) Prior VTE 0 Presence of central line 7 (54%) BMI >30 2 (15%) Exogenous Estrogens 2 (15%) Chemotherapy 13 (100%) Smoking 2 (15%) Advanced Disease 11 (85%) No significant financial relationships to disclose.
Differential Growth Inhibition in Two Human Carcinoma Cell Lines by Cyclic Adenosine 5′-Monophosphate Analogs&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: R M Niles, K W Ludwig, J S Makarski
Journal: JNCI Journal of the National Cancer Institute (1979)

The inhibition of cell replication in two human carcinoma cell lines by various cyclic AMP analogs was explored. In all instances, the addition of the cyclic nucleotide phosphodiesterase inhibitor 1-methyl-3-isobutylxanthine resulted in synergistic growth inhibition by the analogs. A correlation was found between an analog's ability to inhibit growth and its ability to activate protein kinase. A differential effect of the breakdown product 8-bromo-AMP (8-BrAMP) on cell replication in the two cell lines was observed; i.e., one cell type was extremely sensitive to inhibition by 8-BrAMP and the growth inhibition could not be reversed by uridine, whereas the other cell type was less sensitive to 8-BrAMP and the growth inhibition was significantly reversed by uridine.
Resection of a large ileal lipoma exhibiting ball-valve prolapse into the cecum with a “grasp-to-retract, ligate, unroof, and let-go” technique
Authors: Ana Ponte, Rolando Pinho, Sílvio Vale, Carlos Fernandes, Iolanda Ribeiro, Joana Silva, João Carvalho
Journal: Endoscopy (2015)

A 51-year-old woman was referred to our department for endoscopic resection of a symptomatic ileal lipoma, which had been detected during a previous colonoscopy performed to investigate a 6-month history of intermittent episodes of abdominal pain and diarrhea. Colonoscopy revealed a large, yellowish, pseudo-pedunculated ileal lesion with normal overlying mucosa that was prolapsed through the ileocecal valve into the cecum ([Fig. 1]).
Safer Prescribing — A Trial of Education, Informatics, and Financial Incentives
Authors: Tobias Dreischulte, Peter Donnan, Aileen Grant, Adrian Hapca, Colin McCowan, Bruce Guthrie
Journal: New England Journal of Medicine (2016)

High-risk prescribing and preventable drug-related complications are common in primary care. We evaluated whether the rates of high-risk prescribing by primary care clinicians and the related clinical outcomes would be reduced by a complex intervention.In this cluster-randomized, stepped-wedge trial conducted in Tayside, Scotland, we randomly assigned participating primary care practices to various start dates for a 48-week intervention comprising professional education, informatics to facilitate review, and financial incentives for practices to review patients' charts to assess appropriateness. The primary outcome was patient-level exposure to any of nine measures of high-risk prescribing of nonsteroidal antiinflammatory drugs (NSAIDs) or selected antiplatelet agents (e.g., NSAID prescription in a patient with chronic kidney disease or coprescription of an NSAID and an oral anticoagulant without gastroprotection). Prespecified secondary outcomes included the incidence of related hospital admissions. Analyses were performed according to the intention-to-treat principle, with the use of mixed-effect models to account for clustering in the data.A total of 34 practices underwent randomization, 33 of which completed the study. Data were analyzed for 33,334 patients at risk at one or more points in the preintervention period and for 33,060 at risk at one or more points in the intervention period. Targeted high-risk prescribing was significantly reduced, from a rate of 3.7% (1102 of 29,537 patients at risk) immediately before the intervention to 2.2% (674 of 30,187) at the end of the intervention (adjusted odds ratio, 0.63; 95% confidence interval [CI], 0.57 to 0.68; P<0.001). The rate of hospital admissions for gastrointestinal ulcer or bleeding was significantly reduced from the preintervention period to the intervention period (from 55.7 to 37.0 admissions per 10,000 person-years; rate ratio, 0.66; 95% CI, 0.51 to 0.86; P=0.002), as was the rate of admissions for heart failure (from 707.7 to 513.5 admissions per 10,000 person-years; rate ratio, 0.73; 95% CI, 0.56 to 0.95; P=0.02), but admissions for acute kidney injury were not (101.9 and 86.0 admissions per 10,000 person-years, respectively; rate ratio, 0.84; 95% CI, 0.68 to 1.09; P=0.19).A complex intervention combining professional education, informatics, and financial incentives reduced the rate of high-risk prescribing of antiplatelet medications and NSAIDs and may have improved clinical outcomes. (Funded by the Scottish Government Chief Scientist Office; ClinicalTrials.gov number, NCT01425502.).
P0365 : Effects of metformin on clinical outcome in advanced HCC patients receiving sorafenib
Authors: A. Caadei Gardini, M. Scartozzi, E. Scarpi, G. Marisi, L. Faloppi, S. Tamberi, E. Tamburini, G. Masi, F.G. Foschi, N. Silvestris, P. Ulivi, G. Luca Frassineti
Journal: Journal of Hepatology (2015)
Geriatric parameters to predict chemotherapy feasibility in elderly patients (≥75 years) with advanced colorectal cancer: Preliminary results of a GERCOR-GEPOG cohort study.
Authors: E. Carola, B. Chibaudel, M. Mabro, S. Kirscher, M. Certain-Duclos, T. Aparicio, A. Mercier-Blas, S. Trager-Maury, T. Cudennec, A. de Gramont
Journal: Journal of Clinical Oncology (2010)

e19512 Background: Oncogeriatry has brought specific assessment in elderly patients (pts). The use of the Comprehensive Geriatric assessment improves survival in elderly pts treated for an advanced colorectal cancer. Methods: The aim of this multicentric prospective cohort study (NCT00664911) was to identify predictive geriatric parameters for the feasibility of chemotherapy (C) in elderly pts. Main pts eligibility criteria were: age ≥75years, previously untreated advanced cancer (colorectal or breast or ovary), initiation of C at ≥2/3 of standard doses. C feasibility was defined as ≤33% dose reduction (DR) during the first three months. Ten baseline parameters were assessed: 1-three words test, 2-date and address for cognitive function, 3-Instrumental Activities of Daily Living (IADL), 4- monopodal stand-up test, 5-hospitalization during the previous year, 6-number of medicines taken for comorbidities, 7-creatinine clearance, 8-albumin serum level, 9-depression and 10-social environment. C regimen was not suggested to investigators. This analysis will focus on patients with colorectal cancer. Results: From April 2008 to December 2009, 90 pts were included (colorectal: n=68; breast, n=12; ovary n=10). Evaluable colorectal cancer pts characteristics (n=65) were: mean age 82 years [75-94], C regimen were oxaliplatin-based in 42 pts (64.6%), irinotecan-based in 9 pts (13.8%), fluoropyrimidine alone in 15 pts (23.1%). A DR >33% was observed in 20 pts (31%). The 10 items geriatric scale resulted in a score with sensitivity (Se) 80%, specificity (Sp) 58%, positive predictive value (PPV) 46%, negative predictive value (NPV) 87%, and Yule's Q was 0.69. Combining three selected items (3,5,6) allowed us to build a new scale with Se 95%, Sp 27%, PPV 36%, NPV 92%, and Yule's Q 0.75. Conclusions: There was a positive association between the 10 items geriatric score and the feasibility of C. The new evaluation scale has to be confirmed in another cohort and in other tumor localization. Inclusion criteria of this ongoing study were enlarged to elderly patients with previously untreated localized or advanced solid tumor eligible to chemotherapy. No significant financial relationships to disclose.
A phase I clinical trial of FOLFIRI in combination with the pancyclin–dependentkinase (CDK) inhibitor flavopiridol
Authors: M. A. Dickson, R. D. Carvajal, M. Shah, A. N. Tse, H. Dials, L. M. Cane, G. K. Schwartz
Journal: Journal of Clinical Oncology (2009)

e14511 Background: Preclinical data indicate that sequential treatment with flavopiridol (F) increases irinotecan- and 5-FU-induced apoptosis. Clinically, F showed promising activity when combined with irinotecan (Shah et al CCR 2005). Methods: We conducted a phase I trial of FOLFIRI + F every 2 weeks in patients (pts) with advanced solid tumors. Based on sequence- dependent inhibition, F was given 3 h after irinotecan but before 5-FU. Two maximum tolerated doses (MTD) were determined: MTD 1 (F over 1 h) and MTD 2 (F 30-min bolus + 4 h infusion). F pharmacokinetics (PK) were determined. Results: Of 74 pts treated, 63 were evaluable for toxicity and 56 for response. Pt characteristics: median age 60 (range 19–83), KPS 90 (70–90), prior regimens 3 (1–10). 39 pts received prior irinotecan. Tumor types: colorectal, gastric, HCC, GE junction, small bowel, pancreas, bile duct, breast, bladder, ovarian, sarcoma, melanoma, anal, urethral, thymic, head &amp; neck, unknown primary. MTD 1 : F 80mg/ m 2 with irinotecan 180mg/m 2 , LV 400mg/m 2 , 5FU: 400mg/m 2 bolus + 2400mg/m 2 over 48 h. Dose-limiting toxicities (DLT) were diarrhea, fatigue, neutropenia, neuropathy. MTD 2 : F 35mg/m 2 bolus + 35mg/m 2 over 4 h with the same FOLFIRI dose. DLTs were diarrhea, neutropenia, and fatigue. Clinical activity included 2 partial responses (small bowel cancer, 10.3 m; bladder cancer, 10 m) and 1 complete response (mucosal melanoma 10.3 m). 22 pts had stable disease (median 5.9 m; range 1.5–25.7 m). Clinical benefit rate (CR + PR + SD for &gt; 3 m) was 39% (22/56). Of 25 pts with colorectal cancer, 11 had as best response SD for &gt; 3m (median 6 m, range 4.2–15.4 m), despite failing ≥ 1 irinotecan-containing regimen. 6 of those had significant decreases (36–78%) in CEA. F PK showed interpatient variability with no significant interaction between FOLFIRI dose and F C max . F C max increased with increasing F dose. At MTDs, there was higher C max in pts who experienced DLT (3.48μM) vs those who did not (2.21μM). Conclusions: F can be safely given as a bolus (80mg/m 2 ) or split dose (35mg/m 2 bolus + 35mg/ m 2 over 4 h) in combination with irinotecan 180mg/m 2 , LV 400mg/m 2 , 5FU: 400mg/m 2 bolus + 2400mg/m 2 over 48 h. Promising clinical activity is seen in mucosal melanoma and irinotecan-refractory colon cancer. (Supported by NCI R01CA67819) [Table: see text]
The Challenges of Stroke Prediction Scores
Authors: Deena M. Nasr, Robert D. Brown
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
Authors: Viktor H. Koelzer, Sacha I. Rothschild, Deborah Zihler, Andreas Wicki, Berenika Willi, Niels Willi, Michèle Voegeli, Gieri Cathomas, Alfred Zippelius, Kirsten D. Mertz
Journal: Journal for ImmunoTherapy of Cancer (2016)

<h3>Background</h3> Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been recently approved for treatment of patients with metastatic melanoma and non-small cell lung cancer (NSCLC). Despite important clinical benefits, these therapies are associated with a diverse spectrum of immune-related adverse events (irAEs) that are typically transient, but occasionally severe or even fatal. <h3>Case presentation</h3> This autopsy case illustrates that clinically overt irAEs may represent only a fraction of the total spectrum of immune-related organ pathology in patients treated with immune checkpoint inhibitors. We report a comprehensive analysis of systemic irAE pathology based on the autopsy of a 35-year-old female patient with metastatic melanoma treated first with ipilimumab and then nivolumab. The clinical course was characterized by a mixed tumor response with regression of skin and lung metastases and fatal progression of metastatic disease in the small bowel, peritoneum and brain. During therapy with ipilimumab, radiographic features of immune-related pneumonitis were noted. The autopsy examination established a sarcoid-like granulomatous reaction of the lung, pulmonary fibrosis and diffuse alveolar damage. Importantly, a clinically unapparent but histologically striking systemic inflammation involving the heart, central nervous system, liver and bone marrow was identified. Severe immune-related end-organ damage due to lymphocytic myocarditis was found. <h3>Conclusions</h3> Autopsy studies are an important measure of quality control and may identify clinically unapparent irAEs in patients treated with immunotherapy. Pathologists and clinicians need to be aware of the broad spectrum of irAEs for timely management of treatment-related morbidity.
Tackle technique and tackle-related injuries in high-level South African Rugby Union under-18 players: real-match video analysis
Authors: Nicholas Burger, Michael I Lambert, Wayne Viljoen, James C Brown, Clint Readhead, Sharief Hendricks
Journal: British Journal of Sports Medicine (2016)

The high injury rate associated with rugby union is primarily due to the tackle, and poor contact technique has been identified as a risk factor for injury. We aimed to determine whether the tackle technique proficiency scores were different in injurious tackles versus tackles that did not result in injury using real-match scenarios in high-level youth rugby union.Injury surveillance was conducted at the under-18 Craven Week tournaments (2011-2013). Tackle-related injury information was used to identify injury events in the match video footage and non-injury events were identified for the injured player cohort. Injury and non-injury events were scored for technique proficiency and Cohen's effect sizes were calculated and the Student t test (p<0.05) was performed to compare injury versus non-injury scores.The overall mean score for front-on ball-carrier proficiency was 7.17±1.90 and 9.02±2.15 for injury and non-injury tackle events, respectively (effect size=moderate; p<0.05). The overall mean score for side/behind ball-carrier proficiency was 4.09±2.12 and 7.68±1.72 for injury and non-injury tackle events, respectively (effect size=large; p<0.01). The overall mean score for front-on tackler proficiency was 7.00±1.95 and 9.35±2.56 for injury and non-injury tackle events, respectively (effect size=moderate; p<0.05). The overall mean score for side/behind tackler proficiency was 5.47±1.60 and 8.14±1.75 for injury and non-injury tackle events, respectively (effect size=large; p<0.01).Higher overall mean and criterion-specific tackle-related technique scores were associated with a non-injury outcome. The ability to perform well during tackle events may decrease the risk of injury and may manifest in superior performance.
Pioneering Activity of the C-Terminal Domain of EBF1 Shapes the Chromatin Landscape for B Cell Programming
Authors: Sören Boller, Senthilkumar Ramamoorthy, Duygu Akbas, Robert Nechanitzky, Lukas Burger, Rabih Murr, Dirk Schübeler, Rudolf Grosschedl
Journal: Immunity (2016)
Evaluation of quality indicators (QIs) for colorectal cancer care in a community setting
Authors: K. Frisby, L. Meyer, J. Lee, M. Mathiason, L. Dietrich
Journal: Journal of Clinical Oncology (2007)

6585 Background: We compared two existing sets of QIs for colorectal cancer care to evaluate our performance as compared to published data. We also explored reasons for non-adherence to these QIs to determine how we could increase our compliance. Methods: Chart review of all patients who were newly diagnosed with colorectal cancer at our institution in 2004 and 2005 for compliance with QIs for colorectal cancer care as presented by National Initiative for Cancer Care Quality (NICCQ) and Moffitt Network Initiative on Practice Quality (MNIPQ). When 85% compliance was not observed, charts were reviewed as to why care differed from QI. Results: Adherence rate was less than 85% in 5 of 25 NICCQ colon cancer measures and patients overall received 83% of recommended care. Reasons for &lt;85% adherence on NICCQ were most often due to patient decision (patient decision after informed discussion, refusal of treatment, patient initiated delay) or co-morbidity (poor wound healing, infection, medical co-morbidity). In one item regarding counseling of family members about colorectal screening we were truly noncompliant without documentation of reason. Review of MNIPQ items observed less than 85% adherence rate in 2 of 9. Reason for non-adherence in MNIPQ review was due most often to co- morbidity, and true noncompliance (no reason documented for lack of pretreatment CEA). Conclusions: Our adherence rates for NICCQ and MNIPQ measures compare favorably with published values. Lower compliance rates on NICCQ and MNIPQ measures were most often due to patient choice or co-morbidities. In setting benchmarks for these individual QIs it should be noted that for some indicators (such as those regarding adjuvant therapy) higher percent adherence does not always reflect better care. Higher compliance may actually mean that thoughtful consideration of patient co-morbidity and complications, or including patients in decision making is not occurring or that the population being served is younger or has fewer co-morbidities. Other indicators such as those regarding staging documentation, documentation of chemotherapy, and patient education factors the higher the compliance the better. We conclude that some sampling of reason for non- adherence is necessary when assessing quality of care. No significant financial relationships to disclose.
Abstract 227: The Association of Body Mass Index with End-Tidal Carbon Dioxide and Return of Spontaneous Circulation Following Cardiac Arrest
Authors: Marion Leary, Marisa Cinousis, Kelsey Sheak, Jiaqi Li, Benjamin S Abella
Journal: Circulation (2013)

Background: End-tidal carbon dioxide (ETCO 2 ) has been shown to correlate with return of spontaneous circulation (ROSC) during cardiac arrest. However, ETCO2 is confounded by a number of factors such as patient physiologic parameters and CPR quality.The relationship of patient Body Mass Index (BMI) to mean intra-arrest ETCO 2 and subsequent ROSC is unknown. Objective: To measure the association of BMI with intra-arrest ETCO 2 and ROSC. Methods: In a single-center cohort of cardiac arrest patients between 7/2007 - 6/2012, we measured ETCO 2 using side-stream capnography during resuscitation efforts, and calculated patient BMI from clinical records. Student’s t-tests were used to compare outcomes. Results: Of the 345 cardiac arrest cases that were recorded, 48 had both BMI and ETCO 2 data available. The mean age of the cohort was 63.1±16.5 yrs, 12/48 (25%) were female and 10/48 (21%) had VF/VT as the initial rhythm, 18/48 (38%) obtained ROSC. When we examined those who obtained ROSC versus those who did not, BMI was significantly less in the cohort that obtained ROSC (23.8±5.9 v 32.0±10.8, p=0.002) and ETCO 2 was higher (34.3±8.9 v 22.4±13.7, p=0.001). There were no statistically significant differences in patient demographics, compression rate or depth between the two groups. Overall, there were no significant interaction between BMI and ETCO 2 (p-value=0.921). Conclusions: BMI was significantly lower and ETCO 2 higher in those patients who had ROSC, though there was not a relationship between BMI and ETCO2, suggesting that ETCO2 can be clinically utilized and interpreted independent of patient habitus.
Abstract 11347: Effect of Prasugrel on Platelet Function Profiles in Non-Diabetic Obese Patients with Coronary Artery Disease
Authors: Andrew T Darlington, Antonio Tello-Montoliu, Fabiana Rollini, Masafumi Ueno, Jose L Ferreiro, Ronakkumar Patel, Bhaloo Desai, Luis A Guzman, Theodore A Bass, Dominick J Angiolillo
Journal: Circulation (2012)

Background: Increased body weight is independently associated with impaired clopidogrel response in patients with coronary artery disease (CAD). Prasugrel has more potent antiplatelet effects compa...